EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies

Kim Papp, Jacek C Szepietowski, Leon Kircik, Darryl Toth, Lawrence F Eichenfield, Seth B Forman, Michael E Kuligowski, Howard Kallender, Kang Sun, Haobo Ren, Eric L Simpson

Journal of the American Academy of Dermatology · 2023-05 · 88 (5) · 1008-1016

DOI: 10.1016/j.jaad.2022.09.060 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the American Academy of Dermatology, 2023-05. Verfasst von Kim Papp und 10 weiteren Autor:innen. Beteiligte Einrichtung: K. Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada. Electronic address: kapapp@probitymedical.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Incyte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in 2 double-blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651). OBJECTIVE: To evaluate long-term safety (LTS) and disease control with ruxolitinib cream. METHODS: Patients initially randomized to twice-daily 0.75%/1.5% ruxolitinib cream maintained their regimen during the 44-week LTS period (as-needed treatment). Patients on vehicle were rerandomized (1:1) at week 8 to either ruxolitinib cream strength. Safety and disease control (Investigator's Global Assessment score 0/1 and affected body surface area) were assessed. RESULTS: Over 52 weeks, adverse events were reported in 67.4%/62.6%/53.5%/57.6% of patients in 0.75%/1.5% ruxolitinib cream/vehicle to 0.75% ruxolitinib cream/vehicle to 1.5% ruxolitinib cream groups (n = 426/446/101/99). Most common adverse events were upper respiratory tract infection (10.3%/11.4%/5.9%/7.1%) and nasopharyngitis (8.9%/9.9%/7.9%/14.1%). Most adverse events were considered unrelated to treatment. Application site reactions were infrequent (3.8%/1.8%/1.0%/1.0%). Disease control was achieved throughout the LTS; 74.1% to 77.8% of patients had Investigator's Global Assessment 0/1 at week 52, and mean affected body surface area was low (1.4%-1.8%). LIMITATIONS: LTS had no control treatment. CONCLUSION: During 44 weeks of as-needed treatment, ruxolitinib cream demonstrated effective disease control and tolerability; low ruxolitinib plasma concentrations alongside safety findings reflecting known risk factors suggest physiologically meaningful systemic Janus kinase inhibition is highly unlikely.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansDouble-Blind MethodEmollientsNitrilesPyrimidinesSeverity of Illness IndexTreatment OutcomePyrazoles

Substanzen

EmollientsNitrilesPyrimidinesruxolitinibPyrazoles

Autor:innen und Institutionen

  • K. Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada. Electronic address: kapapp@probitymedical.com.
  • Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
  • Icahn School of Medicine at Mount Sinai, New York, New York.
  • XLR8 Medical Research and Probity Medical Research, Windsor, Ontario, Canada.
  • Departments of Dermatology and Pediatrics, University of California San Diego, San Diego, California.
  • ForCare Clinical Research, Tampa, Florida.

Förderung

  • Incyte

Zitieren

APA

Papp, K., Szepietowski, J. C., Kircik, L., Toth, D., Eichenfield, L. F., Forman, S. B., Kuligowski, M. E., Kallender, H., Sun, K., Ren, H., & Simpson, E. L. (2023). Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology, 88(5), 1008-1016. https://doi.org/10.1016/j.jaad.2022.09.060

Vancouver

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology. 2023;88(5):1008-1016. doi:10.1016/j.jaad.2022.09.060

BibTeX
@article{Papp2023,
  author = {Papp, Kim and Szepietowski, Jacek C and Kircik, Leon and Toth, Darryl and Eichenfield, Lawrence F and Forman, Seth B and Kuligowski, Michael E and Kallender, Howard and Sun, Kang and Ren, Haobo and Simpson, Eric L},
  title = {Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies},
  journal = {Journal of the American Academy of Dermatology},
  year = {2023},
  volume = {88},
  number = {5},
  pages = {1008--1016},
  doi = {10.1016/j.jaad.2022.09.060}
}
Kostenlos starten →